Dactus 2 mg Tablet is a medicine for type 2 diabetes, used alongside diet and exercise when blood sugar stays too high. It contains glimepiride, a sulfonylurea that helps the body release more insulin.
There are 41 brands of Glimepiride listed in Bangladesh. 19 of them have a lower unit price than Dactus. The lowest listed price is Mepid 1 mg Tablet at ৳ 2.51 per unit.
What is Dactus 2 mg Tablet?
Dactus 2 mg Tablet is an oral diabetes medicine made by The ACME Laboratories Ltd. It belongs to the sulfonylurea group and contains glimepiride. Doctors prescribe it for adults with type 2 diabetes when diet and exercise alone do not control blood sugar. It can also be used with metformin if one medicine is not enough. Glimepiride works by prompting the pancreas to release more insulin, which helps lower blood sugar. Dactus is a tablet taken by mouth. The dose and how often you take it are decided by your doctor based on your blood sugar tests. Always follow your doctor's instructions and keep regular check-ups.
Uses of Dactus
Dactus 2 mg Tablet is used to treat type 2 diabetes in adults. It is prescribed when diet and exercise alone are not enough to keep blood sugar under control. It can also be combined with metformin when either medicine alone does not work well enough. This medicine is not for type 1 diabetes or for diabetic emergencies such as ketoacidosis or diabetic coma. Your doctor will decide if Dactus is suitable for you based on your health and blood sugar levels.
How to use Dactus
Take Dactus 2 mg Tablet exactly as your doctor tells you. The doctor decides the dose and how often you take it; never change the dose yourself. Swallow the tablet with water. It is important to keep to your diet and exercise plan while taking this medicine. Your doctor will check your blood sugar regularly and may adjust the dose. If you miss a dose, ask your doctor or pharmacist what to do. Do not stop taking Dactus without talking to your doctor first.
Side effects of Dactus
The most common side effect of Dactus is low blood sugar (hypoglycaemia), especially in the first weeks of treatment. Symptoms may include sweating, shakiness, hunger, dizziness, or confusion. If you think your blood sugar is low, take a fast source of sugar such as glucose tablets or sugary drink, as your doctor advises. Other side effects can include temporary vision changes, nausea, vomiting, diarrhoea, stomach pain, skin rash, and a drop in blood pressure. Tell your doctor if any side effect bothers you or does not go away.
Safety and precautions
Dactus is not for everyone. It must not be used in type 1 diabetes, diabetic ketoacidosis, or diabetic coma. Do not take it if you are allergic to glimepiride, other sulfonylureas, or sulfonamides, or if you have severe liver or kidney problems or are on dialysis. It is not to be taken during pregnancy or while breastfeeding; insulin is needed instead. If you are planning a pregnancy, tell your doctor before you start. The risk of low blood sugar may be higher in the first weeks, so careful monitoring is needed. Always ask your doctor before starting or stopping this medicine.
Frequently asked questions
What is Dactus 2 mg Tablet used for and what kind of medicine is it?
It is used to treat type 2 diabetes in adults when diet and exercise are not enough. It contains glimepiride, a sulfonylurea that helps the pancreas release more insulin. It can also be used with metformin. Your doctor will decide if it is right for you.
How should Dactus 2 mg Tablet be taken?
Take it exactly as your doctor prescribes. The doctor decides the dose and how often you take it. Swallow the tablet with water and keep to your diet and exercise plan. Do not change the dose yourself. If you miss a dose, ask your doctor or pharmacist what to do.
What does the dosage form and strength mean?
Dactus comes as a tablet, which is taken by mouth. The strength is 2 mg, meaning each tablet contains 2 milligrams of glimepiride. Your doctor will decide how many tablets you need. The pack size is 6 x 10, which is a carton of six strips of ten tablets.
Glimepiride is indicated as an adjunct to diet and exercise to lower the blood glucose in patients with noninsulin dependent (Type II) diabetes mellitus (NIDDM) whose hyperglycaemia cannot be controlled by diet and exercise alone.
Glimepiride may be used concomitantly with metformin when diet, exercise, and Glimepiride or metformin alone does not result in adequate glycaemic control.
... Read more
Glimepiride is indicated in following conditions-
Glimepiride is indicated as an adjunct to diet and exercise to lower the blood glucose in patients with noninsulin dependent (Type II) diabetes mellitus (NIDDM) whose hyperglycaemia cannot be controlled by diet and exercise alone.
Glimepiride may be used concomitantly with metformin when diet, exercise, and Glimepiride or metformin alone does not result in adequate glycaemic control.
Glimepiride is also indicated for use in combination with insulin to lower blood glucose in patients whose hyperglycaemia cannot be controlled by diet and exercise in conjunction with an oral hypoglycaemic agent.
Combined use of Glimepiride and insulin may increase the potential for hypoglycaemia.
Pharmacology
Glimepiride is a sulfonylurea antidiabetic agent which decreases blood glucose concentration. The primary mechanism of action of Glimepiride appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells. Glimepiride acts in concert with glucose by improving the sensitivity of beta cells to physiological glucose stimulus, resulting in insulin secretion. In addition, extrapancreatic effects like reduction of basal hepatic glucose production, increased peripheral tissue sensitivity to insulin and glucose uptake may also play role in the activity of Glimepiride. In non-fasting diabetic patients, the hypoglycaemic action of a single dose of Glimepiride persists for 24 hours.
Dosage & Administration
In principle, the dosage of Glimepiride is governed by the desired blood sugar level. The dosage of Glimepiride must be the lowest which is sufficient to achieve the desired metabolic control. The initial and the maintenance doses are set based on the results of regular check of glucose in blood and urine. Monitoring of glucose levels in blood and urine also serves to detect either primary or secondary failure of therapy.
Initial dose and dose titration: the usual initial dose is 1 mg once daily, if necessary, the daily dose can be increased. Any increase can be based on regular blood sugar monitoring, and should be gradual, i.e., at intervals of 1 to 2 weeks, and carried out stepwise, as follows: 1 mg -> 2 mg -> 3 mg -> 4 mg -> 6 mg.
Dose in patients with well controlled diabetes: the usual dose range in patients with well controlled diabetes is 1 to 4 mg daily.
Distribution of doses: Timing and distribution of doses are decided by the physician, in consideration of the patient's current life-style. Normally, a single daily dose is sufficient. This should be taken immediately before a substantial breakfast or if none is taken immediately before the first main meal. It is very important not to skip meals after taking the drug.
Secondary dosage adjustment: As control of diabetes improves, sensitivity to insuiin increases; therefore, Glimepiride requirement may fall as treatment proceeds. To avoid hypoglycaemia, timely dose reduction or cessation of Glimepiride therapy must be considered. A dose adjustment must also be considered whenever the patient's weight or life-styie changes, or other factors arise which cause an increased susceptibility to hypo or hyperglycaemia.
Changeover from other oral antidiabetics to Glimepiride: There is no exact dosage relationship between Glimepiride and other oral blood sugar lowering agents. When substituting Glimepiride for other such agents, the initial daily dose is 1 mg; this applies even in changeover from maximum dose of other oral blood sugar lowering agents. Any dose increase should be in accordance with guideline given above in 'initial dose and dose titration'. Consideration must be given to the potency and duration of action of the previous blood sugar lowering agent. It may be necessary to interrupt treatment to avoid additive effects which would increase the risk of hypoglycaemia.
Interaction
Based on experience with Glimepiride and known interactions for other sulfonylureas, the following interactions must be considered.
In addition to insulin and other oral antidiabetic agents, drugs which may potentiate the hypoglycaemic action of Glimepiride include: ACE inhibitors, aminosalicylic acid, anabolic steroids and male sex hormones, azapropazone, chloramphenicol, ciofibrate, coumarin derivatives, cyclophosphamide, disopyramide, fenfluramine, fenyramidol, fibrates, fluconazole, fluoxetine, guanethidine, ifosfamide, MAO-inhibitors, miconazole, oxpentifylline (high dose parenteral), oxyphenbutazone, para-aminosalicylic acid, phenylbutazone, probenecid, quinolones, salicylates, sulphinpyrazone, sulfonamide antibiotics, tetracyclines, tritoqualine, trofosfamide.
Drugs which may attenuate the hypoglycaemic action of Glimepiride include:
H2 receptor antagonists, beta-blockers, clonidine and reserpine may lead to either potentiation or weakening of the blood-glucose-lowering effect.
Concomitant treatment with a beta-receptor blocker, clonidine, guanethidine or reserpine may mask the warning symptoms of a hypoglycaemic attack.
Acute and chronic aicohol intake may either potentiate or attenuate the activity of Glimepiride in an unpredictable fashion.
Contraindications
Glimepiride is not suitable for the treatment of insulin dependent (type I) diabetes mellitus, or for the treatment of diabetic ketoacidosis, nor for the treatment of diabetic coma. Glimepiride must not be used in patients hypersensitive to Glimepiride, other sulfonylureas, other sulfonamides, severe hepatic dysfunction, severe impairment of renal function and dialysis patients.
Side Effects
Hypoglycaemia, temporary visual impairment, nausea, vomiting, diarrhoea, abdominal pain, urticaria, fall in blood pressure.
Pregnancy & Lactation
Glimepiride must not be taken during pregnancy; a changeover to insulin is necessary. Patients planning a pregnancy must inform their physician, and should change over to insulin. Ingestion of Glimepiride with breast milk feeding may harm the child. Therefore, Glimepiride must not be taken by breastfeeding women. Either a changeover or complete discontinuation of breastfeeding is necessary.
Precautions & Warnings
in the initial weeks of treatment, the risk of hypoglycaemia may be increased and necessitates careful monitoring. If such risk present it may be necessary to adjust the dosage of Glimepiride, Hypoglycaemia can almost be promptly controlled by immediate intake of carbohydrates (glucose or sugar).
Overdose Effects
Overdosage of sulfonylureas, including Glimepiride, can produce hypoglycaemia. Mild hypoglycaemic symptoms without loss of consciousness or neurologic findings should be treated aggressively with oral glucose and adjustments in drug dosage or meal patterns. Close monitoring should continue until the physician is assured that the patient is out of danger. Severe hypoglycaemic reactions with coma, seizure, or other neurological impairment occur infrequently, but constitute medicai emergencies requiring immediate hospitalization. If hypoglycaemic coma is diagnosed or suspected, the patient should be given a rapid intravenous injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of a more dilute (10%) glucose solution at a rate that will maintain the blood glucose at a level above 100 mg/dl. Patients should be closely monitored for a minimum of 24 to 48 hours, because hypoglycaemia may recur after apparent clinical recovery.
Storage Conditions
Do not store above 30°C. Keep away from light and out of the reach of children.
Alternative brands of Glimepiride
Other brands with the same generic name, cheapest first.